Fig. 1From: Characteristics of drugs for ultra-rare diseases versus drugs for other rare diseases in HTA submissions made to the CADTH CDRa Drug for rare diseases submissions, including resubmissions of drugs with same indication due to the availability of new evidence that may change the original recommendation. b Unique submissions of drugs for rare diseases, where we considered only the latest submission of drugs with multiple submissions for the same indicationBack to article page